Phase 3 Trial of SPECT/CT Imaging for Lung Cancer
Researchers are attempting to determine whether SPECT/CT imaging is non-inferior to PET/CT imaging for lung cancer.
Title: A Multicenter Phase 3 Study Comparing the Diagnostic Accuracy of 99mTc EC DG SPECT/CT Versus 18F FDG PET/CT for Diagnosing and Staging Patients Who Have Clinical and Radiological (CT) Evidence Consistent With a Diagnosis of Lung Cancer1
Responsible Party: Cell>Point LLC
Description: For this non-randomized, open label, phase 3 study (ClinicalTrials.gov Identifier: NCT01394679), researchers are attempting to determine whether lung cancer diagnosis and staging using SPECT/CT 99mTC [technetium]-EC-DG [ethylenedicysteine-deoxyglucose] scanning is non-inferior to PET/CT 18F-FDG scanning.
Patients will undergo PET/CT imaging or SPECT/CT imaging. The primary outcomes are a comparison of the imaging techniques and non-inferiority of SPECT/CT; the secondary outcome is safety.
For more study information, including inclusion and exclusion criteria, study locations, and contact information, visit https://clinicaltrials.gov/ct2/show/NCT01394679.
Status: This study is open and recruiting patients as of April 14, 2017.
This study is sponsored by Cell>Point LLC.
- Clinicaltrials.gov. A phase 3 study of 99mTC-EC-DG SPECT/CT versus PET/CT in lung cancer. NCT01394679. https://clinicaltrials.gov/ct2/show/NCT01394679. Accessed April 14, 2017.